Literature DB >> 1536276

Differential response of seven subjects with autistic disorder to clomipramine and desipramine.

C T Gordon1, J L Rapoport, S D Hamburger, R C State, G B Mannheim.   

Abstract

OBJECTIVE: Clomipramine, a serotonin reuptake blocker that has unique antiobsessional properties, was hypothesized to have a different effect from that of desipramine, a tricyclic antidepressant with selective adrenergic effects, for the stereotyped, repetitive behaviors in autism.
METHOD: Seven subjects, ages 6-18 years, with autistic disorder completed a 10-week double-blind, crossover trial of clomipramine and desipramine following a 2-week single-blind, placebo phase.
RESULTS: Clomipramine was superior to desipramine and placebo, as indicated by standardized ratings of autism and anger as well as ratings of repetitive and compulsive behaviors. Clomipramine and desipramine were equally superior to placebo for ratings of hyperactivity. Parents of all seven subjects elected to have their children continue to take clomipramine after the study.
CONCLUSIONS: Clomipramine and desipramine are differentially effective in treating the obsessive-compulsive and core symptoms in autistic disorder. Biological links between compulsions and stereotyped, repetitive behaviors in autistic disorder should be explored.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1536276     DOI: 10.1176/ajp.149.3.363

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  12 in total

1.  Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors.

Authors:  C J McDougle; L E Kresch; D J Posey
Journal:  J Autism Dev Disord       Date:  2000-10

Review 2.  Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders.

Authors:  M G Aman; K S Langworthy
Journal:  J Autism Dev Disord       Date:  2000-10

Review 3.  Brief report: psychopharmacology of autism spectrum disorders.

Authors:  M H Lewis
Journal:  J Autism Dev Disord       Date:  1996-04

4.  Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study.

Authors:  Andrés Martin; Kathleen Koenig; George M Anderson; Lawrence Scahill
Journal:  J Autism Dev Disord       Date:  2003-02

5.  High-dose pyridoxine and magnesium administration in children with autistic disorder: an absence of salutary effects in a double-blind, placebo-controlled study.

Authors:  R L Findling; K Maxwell; L Scotese-Wojtila; J Huang; T Yamashita; M Wiznitzer
Journal:  J Autism Dev Disord       Date:  1997-08

Review 6.  Affective disorders in people with autism: a review of published cases.

Authors:  J E Lainhart; S E Folstein
Journal:  J Autism Dev Disord       Date:  1994-10

7.  Paraphilias: a double-blind crossover comparison of clomipramine versus desipramine.

Authors:  M J Kruesi; S Fine; L Valladares; R A Phillips; J L Rapoport
Journal:  Arch Sex Behav       Date:  1992-12

8.  Chronic desipramine treatment rescues depression-related, social and cognitive deficits in Engrailed-2 knockout mice.

Authors:  J Brielmaier; J M Senerth; J L Silverman; P G Matteson; J H Millonig; E DiCicco-Bloom; J N Crawley
Journal:  Genes Brain Behav       Date:  2014-03       Impact factor: 3.449

Review 9.  Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders.

Authors:  Michael G Aman; Cristan A Farmer; Jill Hollway; L Eugene Arnold
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2008-10

Review 10.  Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan.

Authors:  Carolyn A Doyle; Christopher J McDougle
Journal:  Dialogues Clin Neurosci       Date:  2012-09       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.